- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03874897
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
February 25, 2022 updated by: Shen Lin, Peking University
An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects
An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2
chimeric antigen receptor T cell in advanced solid tumor.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is an open, single/multiple infusion, dose escalation/dose regimen finding study to assess the safety and pharmacokinetics of CAR-CLDN18.2 T cell therapy, and to obtain the preliminary efficacy results in subjects who have been diagnosed with advanced solid tumor with positive claudin 18.2 expression and failed to standard systemic treatment.
Study Type
Interventional
Enrollment (Anticipated)
123
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lin Shen
- Phone Number: 861088196561
- Email: linshenpku@163.com
Study Contact Backup
- Name: Jifang Gong
- Phone Number: 861088196561
- Email: goodjf@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Department of GI Oncology, Peking University Cancer Hospital
-
Contact:
- Lin Shen, MD,phD
- Phone Number: (86)10-88196561
- Email: linshenpku@163.com
-
Contact:
- Jifang gong, MD,phD
- Phone Number: (86)10-88196561
- Email: goodjf@163.com
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- Recruiting
- The First Affiliated hospital of Zhengzhou University
-
Contact:
- Yanru Qin, MD
- Phone Number: (86)0371-66271156
- Email: yanruqin@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Recruiting
- The First Affiliated Hospital , Zhejiang University School of Medicine
-
Contact:
- Weijia Fang
- Phone Number: (86)0571-87236560
- Email: dr.weijiafang@139.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18 to 75 years, male or female;
- Subjects with pathologically confirmed solid tumors (ie, advanced gastric cancer, esophagogastricgastroesophageal junction cancer, and pancreatic cancer) and have been failed to at least first-one prior line of systemic treatment;
- Tumor tissue samplessample was positive for claudin 18.2 positive through for claudin18.2 IHC staining;assay(≥2+, and ≥40%);
- Estimated life expectancy > 12 weeks;
- According to the RECIST 1.1, there is at least one measurable or unmeasurable tumor lesionslesion;
- ECOG physical status score 0 ~ 1, within 24 hours prior to apheresis, and at baseline (prior to pre-treatment);
- Sufficient venous access for mononuclear cell collection (abbreviation: apheresis)
- Subjects should have adequate organ functions before screening and pre-treatment (at baseline).
- Female subjects of childbearing age must undergo a serum pregnancy test at screening and prior to preconditioning and the results must be negative, and are willing to use a very effective and reliable method of contraception within 1 year after the last study treatment. The methods that can be used are: bilateral tubal ligation / bilateral salpingectomy or bilateral tubal occlusion; or approved oral, injection or hormone-imparting contraceptive methods; or barrier contraceptive method: containing spermicidal foam / Gel/film/cream/suppository condom or occlusive cap (diaphragm or cervix/cap);
- Men who have actively sexual intercourse with women with child-bearing potential, must agree to use barrier-based contraception if they have no vasectomy, for example, a condom containing a spermicidal foam/gel/film/paste/suppository, or use a contraceptive method for their spouse (see article 9 of the inclusion criteria). Moreover, all men are absolutely forbidden to donate sperm within 1 year after receiving the last study treatment infusion;
- Subject participates in this clinical trial and sign Informed Consent Form voluntarily.
Exclusion Criteria:
- Pregnant or lactating women;
- HIV, Treponema pallidum or HCV serologically positive;
- Any uncontrollable active infection, including but not limited to active tuberculosis, HBV infection (HBsAg positive, or HBcAb positive and HBV DNA positive);
- Subjects have clinically significant thyroid dysfunction determined by investigator (serum thyroid hormone assays TT4, TT3, FT3, FT4, and serum thyroid stimulating hormone TSH) which is not suitable for entering into the study;
- The side effects caused by the previous treatment of the subjects did not return to CTCAE ≤1; except hair loss and, hyperpigmentation or other tolerable events determined by investigator or laboratory abnormalities allowed by the protocol;
- Subjects who are using steroidshave recieved ≥15 mg/day glucocorticoid systemically currently within 7 days prior to apheresis; those using inhaled steroids recently or currently are not excluded;
- Previously allergic to immunotherapy and related drugs, history of severe allergiespreconditioning drug such as cyclophosphamide, fludarabine, or allergiestocilizumab or allergic to components of CT041CAR-CLDN18.2T injection, allergic to β-lactam antibiotics;the CT041 infusion;
- Previously received any chimeric antigen receptor-modified T-cells(including CAR-T、TCR-T) .
- Subjects have untreated or symptomatic brain metastases;
- Subjects have central or extensivelywith centralcor diffused metastases in lung and .extensiveor diffused metastases in liver;liveror with rapid tumor progression since screening period evaluated by the investigator preconditioning (at baseline);
- The largest target tumor lesion>4cm
- Subjects with unstable or active ulcers and gastrointestinal bleeding currently;
- Subjects with a history of organ transplantation or awaiting organ transplantation;
- Subjects requiring anticoagulant therapy;
- Subjects requiring continuous anti-platelet therapy;
- Subjects who have undergone major surgery or significant trauma within 4 weeks prior to apheresis, or who are expected to undergo major surgery during the study;
- There are no other serious diseases that may limit subjects' participation in this trial;
- The investigator assessed that the subject was unable or unwilling to comply with the requirements of the study protocol;
- Blood oxygen saturation ≤ 95% before pre-treatmentapheresis or preconditioning (accept finger oxygen detection method);
- Prior to pretreatmentpreconditioning, subjects developed, including but not limited to, new arrhythmias that could not be controlled with drugs, hypotension requiring pressor agent, bacterial, fungal or viral infections that required intravenous antibiotics. Creatinine clearance rate <40mL / min; The investigator judges that the subject is not suitable for continuing the trial. Subjects who use antibiotics to prevent infection can continue the trials if judged by the investigator;
- The subject has a central nervous system disease sign or an abnormal neurological test result with clinical significance;
- The subject is currently suffered from or have suffered from other incurable malignant tumors within previous 3 years, except in situ cervical cancer or skin basal cell cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAR-CLDN18.2 T-Cells
The subjects enrolled will be sequentially assigned to the corresponding dose level.
|
Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses • Chimeric Antigen Receptor T Cells Targeting Claudin18.2
Other Names:
Chimeric Antigen Receptor T Cells Targeting Claudin18.2
with PD-1
Other Names:
First-line systemic therapy according to physician's choice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: 28 days of single infusion
|
Safety
|
28 days of single infusion
|
Maximum tolerated dose (MTD)
Time Frame: 28 days of single infusion
|
tolerability
|
28 days of single infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (the number of cell copies and cell persistence duration in peripheral blood)
Time Frame: 26 weeks
|
CAR-CLDN18.2 DNA in peripheral blood detected by q-PCR at each visit after infusion
|
26 weeks
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: 1 year
|
Adverse events occurring through 26 weeks and 12 months post infusion of CAR-CLDN18.2 T-Cell infusion, such as abnormalities or changes in laboratory examinations, physical examinations, vital signs, etc.
|
1 year
|
Antitumor efficacy-Progression-free survival (PFS)
Time Frame: 1 year
|
The period from the day when the subject receives the infusion of cells to the first recorded tumor progression (whether treated or not) or death of any cause, which occurs first.
|
1 year
|
Antitumor efficacy-Duration of response (DOR)
Time Frame: 1 year
|
The period from the first evaluation of CR or PR to the first evaluation of PD or death of any cause
|
1 year
|
Antitumor efficacy-Duration of disease control (DDC)
Time Frame: 1 year
|
The period from the first evaluation of clinical benefit to the first evaluation of PD or any cause of death.
|
1 year
|
Antitumor efficacy-Overall survival (OS)
Time Frame: 1 years
|
The period from the first infusion to any cause of death
|
1 years
|
Antitumor efficacy-Objective response rate (ORR)
Time Frame: 1 year
|
The number of cases in which tumor size is reduced to PR or CR / the total number of evaluable cases (%).
In the event of PR or CR, the subjects should confirm it no less than 4 weeks after the first evaluation
|
1 year
|
Antitumor efficacy-Disease control rate (DCR)
Time Frame: 1 year
|
The number of cases in which response are achieved from the start of cell infusion/the total number of evaluable cases (%).
|
1 year
|
Long term survival follow up
Time Frame: 15 years
|
The period from the first infusion to any cause of death
|
15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 26, 2019
Primary Completion (Actual)
March 20, 2021
Study Completion (Anticipated)
March 20, 2024
Study Registration Dates
First Submitted
March 11, 2019
First Submitted That Met QC Criteria
March 12, 2019
First Posted (Actual)
March 14, 2019
Study Record Updates
Last Update Posted (Actual)
March 14, 2022
Last Update Submitted That Met QC Criteria
February 25, 2022
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT041-CG4006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on CAR-CLDN18.2 T-Cells
-
Sichuan UniversityNot yet recruitingAdvanced Solid TumorChina
-
Peking UniversityAstraZenecaRecruiting
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States